NewsRelease
ResearchArticle Cites HemogloBind™ in Malaria Study of Reticulocytes
MONMOUTHJUNCTION, NJ, July31, 2018 --Biotech Support Group reports on a recent research article describingthesimplicity and efficiency of their hemoglobin depletion technologyfor improving Western blot analysis from reticulocytes. The citationis:
Junqueira,Caroline, et al. "CytotoxicCD8+ T cells recognize and kill Plasmodium vivax–infectedreticulocytes." Naturemedicine(2018):1.
TheMalaria parasite Plasmodiumvivax causesapproximately 100 million clinical cases yearly. The basis ofprotective immunity is poorly understood yet thought to be mediatedby antibodies. The authors hypothesized that CD8+T Cells in patient with P.vivax malaria mightbecome activated by recognizing P.vivax-infectedreticulocytes (iRetics), causing them to degranulate. Toevaluate the expression levels of proteins involved in antigenpresentationinreticulocytes by Western blot, thearticle states “Cell lysates of reticulocytes…were analyzed byimmunoblot…after hemoglobin removal using HemogloBind™ (BiotechSupport Group)”. The authors conclude that P.vivax rendersreticulocytes granulysin-susceptible and that this unexpected T Celldefense might be mobilized to improve vaccines.
“Thelarge amount of hemoglobin in whole blood presents a specialchallenge for quantitative Western blot analysis. Here is anotherarticle demonstrating that HemogloBind™ can reduce the interferenceassociated with large concentrations of hemoglobin, withoutcompromising the recovery and analysis of the protein of interest.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information on HemogloBind™, visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866,[email protected]